Clinical trial
FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor…
NCT00325442 · United Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00325442 |
|---|---|
| Title | FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH) |
| Official title | A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects With Pulmonary Arterial… |
| Lead sponsor | United Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pulmonary Hypertension |
| Intervention type | Drug |
| Interventions | Oral treprostinil (UT-15C) sustained release tablets, Placebo |
| Enrollment | 354 |
| Start date | Oct 1, 2006 |
| Primary completion | Sep 1, 2008 |
| Completion | Dec 1, 2010 |
| First posted | May 12, 2006 |
| Last update posted | Aug 2, 2017 |
| Countries | Australia, Austria, Belgium, Canada, France, Germany, Ireland, Israel, Italy, Netherlands, Poland, Spain and 2 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: